


PRODUCT INFORMATION



KRN 633

Item No. 14871

CAS Registry No.: 286370-15-8
Formal Name: N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyloxy)phenyl]-N'-propyl-urea
MF: C₂₀H₂₁ClN₄O₄
FW: 416.9
Purity: ≥95%
UV/Vis.: λ_{max}: 210, 242, 320 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

KRN 633 is supplied as a crystalline solid. A stock solution may be made by dissolving the KRN 633 in the solvent of choice, which should be purged with an inert gas. KRN 633 is soluble in organic solvents such as DMSO and dimethyl formamide (DMF). The solubility of KRN 633 in these solvents is approximately 0.3 and 10 mg/ml, respectively.

KRN 633 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, KRN 633 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. KRN 633 has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

KRN 633 is an ATP-competitive inhibitor of VEGFR kinase activity (IC₅₀s = 170, 160, and 125 nM for VEGFR1, 2, and 3, respectively).¹ At higher concentrations KRN 633 inhibits PDGFR-α and c-KIT with IC₅₀ values of 0.97 and 4.3 μM, respectively, and is inactive towards a panel of 17 additional kinases.¹ KRN 633 suppresses VEGF-dependent activation of MAPK and cell proliferation and demonstrates antitumor and antiangiogenic activity by inhibiting vessel formation and vascular permeability in human tumor xenograft models.²

References

1. Fedorov, O., Marsden, B., Pogacic, V., *et al.* A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. *Proc. Natl. Acad. Sci. USA* **104**(51), 20523-20528 (2007).
2. Nakamura, K., Yamamoto, A., Kamishohara, M., *et al.* KRN633: A selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase that suppresses tumor angiogenesis and growth. *Mol. Cancer Ther.* **3**(12), 1639-1649 (2004).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/27/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM